Lantheus (LNTH) Proxy filing summary

Executive summary

• Entered into a definitive merger agreement for acquisition by Curium US Holdings LLC, with shareholders to receive $102.50 per share in cash plus a contingent value right (CVR) of up to $12.00 per share based on future milestones.

• The merger is subject to customary closing conditions, including regulatory approvals and shareholder approval, with no financing contingency.

• Termination provisions include reciprocal fees: $228 million payable by the company and up to $385 million by the acquirer under certain circumstances.

• The CVR structure incentivizes achievement of commercial milestones in prostate cancer, neurology, and DEFINITY franchises through 2030.

• Forward-looking statements highlight risks related to regulatory approvals, milestone achievement, integration, and market conditions.

Voting matters and shareholder proposals

• Shareholders will vote on the adoption of the merger agreement at a special meeting following SEC clearance of the proxy statement.

• Approval requires a majority of outstanding shares entitled to vote.

• Board may change its recommendation in response to a superior proposal or intervening event, subject to notice and negotiation rights for the acquirer.

Board of directors and corporate governance

• The board unanimously determined the merger is in the best interests of shareholders and recommends approval.

• Post-merger, directors and officers of the acquirer's subsidiary will become directors and officers of the surviving corporation.

• Directors are required to resign at closing.